The impact of anemia on quality of life in human immunodeficiency virus-infected patients

被引:41
作者
Volberding, P [1 ]
机构
[1] Univ Calif San Francisco, Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA
关键词
D O I
10.1086/340198
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anemia is the most commonly encountered hematologic abnormality in human immunodeficiency virus (HIV)-positive patients, occurring with increasing frequency as the disease progresses. Several factors play a role in the development of anemia in patients with HIV, including chronic disease, opportunistic infections, and certain nutritional deficiencies. Despite the high prevalence of anemia in this population, the symptoms of anemia are frequently overlooked, although anemia can significantly affect a patient's ability to carry on even normal activities of daily living. Therefore, approaches-including the treatment of causative infections, discontinuation of certain drugs, or use of recombinant human erythropoietin (epoetin alfa)-aimed at increasing hemoglobin levels to normal or near-normal levels would be expected to improve quality of life (QOL). The purpose of this article is to describe the effects of anemia on QOL and to provide an overview of several studies showing that QOL improves with the alleviation of anemia.
引用
收藏
页码:S110 / S114
页数:5
相关论文
共 22 条
[1]   Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life [J].
Abrams, DI ;
Steinhart, C ;
Frascino, R .
INTERNATIONAL JOURNAL OF STD & AIDS, 2000, 11 (10) :659-665
[2]  
Barroso J, 1999, J Assoc Nurses AIDS Care, V10, P42, DOI 10.1016/S1055-3290(06)60342-7
[3]   Fatigue in ambulatory AIDS patients [J].
Breitbart, W ;
McDonald, MV ;
Rosenfeld, B ;
Monkman, ND ;
Passik, S .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 15 (03) :159-167
[4]  
Cella D, 1998, SEMIN ONCOL, V25, P43
[5]   Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects [J].
Cheung, WK ;
Goon, BL ;
Guilfoyle, MC ;
Wacholtz, MC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :412-423
[6]  
CLEELAND CS, 1999, 35 ANN PROGR P AM SO, pA574
[7]   ON THE RECEIVING END .2. LINEAR ANALOG SELF-ASSESSMENT (LASA) IN EVALUATION OF ASPECTS OF THE QUALITY OF LIFE OF CANCER-PATIENTS RECEIVING THERAPY [J].
COATES, A ;
DILLENBECK, CF ;
MCNEIL, DR ;
KAYE, SB ;
SIMS, K ;
FOX, RM ;
WOODS, RL ;
MILTON, GW ;
SOLOMON, J ;
TATTERSALL, MHN .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (11) :1633-1637
[8]  
DARKO DF, 1992, AM J PSYCHIAT, V149, P514
[9]   Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study [J].
Demetri, GD ;
Kris, M ;
Wade, J ;
Degos, L ;
Cella, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3412-3425
[10]   Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing [J].
Gabrilove, JL ;
Cleeland, CS ;
Livingston, RB ;
Sarokhan, B ;
Winer, E ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2875-2882